EvoPAR-PR02Recruiting

Efficacy of Saruparib (AZD5305) in High-Risk Prostate Cancer with a BRCA Mutation

Gender
Men
Age
18 years and older
Trial type
Interventional
Line of therapy
all
Phase
Phase III

What is this trial about?

Men with that is at high risk of or spreading often require intensive treatments to prevent metastases. If certain gene are detected, a more targeted treatment—for example, with the saruparib, which has not yet been approved—could help better control the disease. The goal of the EvoPAR-PR02 study is to investigate whether adding the drug saruparib (AZD5305) to standard treatment (radiation therapy and anti-hormone therapy) can delay the onset of metastases more effectively than standard treatment alone. Men aged 18 and older who have localized or locally advanced high-risk prostate cancer and carry a BRCA mutation are eligible to participate in the study.

Trial flow

Requirements

Diagnosis: prostate cancer

Age: 18 years and older

Key inclusion criteria: high-risk & very high-risk localised/locally advanced; or biochemical recurrence; BRCA1- or BRCA2-gene-mutation; metastases-free; past radiation;

Allocation

Randomisierung

Treatment

Androgen Deprivation Therapy + Saruparib
Androgen Deprivation Therapy + Placebo
Androgen Deprivation Therapy + Abiraterone (+ Prednisone/Prednisolone) + Saruparib
Androgen Deprivation Therapy + Abiraterone (+ Prednisone/Prednisolone) + Placebo

Follow-up

132 months

Detailed description

Prostate cancer (prostate carcinoma) is one of the most common cancers in men. In many patients, the cancer is confined to the prostate or has spread only to the surrounding tissue (locally advanced). However, if the cancer exhibits certain characteristics, such as a high prostate-specific antigen (PSA) level or aggressive cell growth, there is a high risk that it will return or spread to other organs in the body (metastasize). A distinctive feature in some patients is a mutation in the BRCA genes (BRCA1 or BRCA2). These genes are normally responsible for repairing DNA damage. If they are defective, cancer cells can multiply more quickly, but they are also more susceptible to certain drugs that exploit this very repair defect.

The standard treatment for high-risk prostate cancer often includes radiation therapy (radiotherapy) combined with (anti-hormone therapy), which lowers the male sex hormone testosterone and thus deprives the cancer of its growth stimulus. The study drug saruparib (AZD5305) is a so-called poly-ADP-ribose polymerase inhibitor () and has not yet been approved in Germany for the treatment of prostate cancer. PARP inhibitors block an enzyme that is also involved in DNA repair. In tumors with a BRCA mutation, the simultaneous blockade of the PARP enzyme and the loss of function of the BRCA genes result in the cancer cells being unable to repair their DNA damage and subsequently dying. The goal of this Phase 3 study is to determine whether saruparib, in combination with standard treatment (radiation therapy and anti-hormone therapy), is more effective than standard treatment alone. Patients will be randomly assigned to two groups within two . Cohort A includes patients with newly diagnosed high-risk prostate cancer or a recurrence following surgery () who are receiving radiation therapy and hormone therapy. They will also receive either saruparib or a . Cohort B includes patients with newly diagnosed very high-risk (locally advanced) prostate cancer who are receiving radiation therapy, hormone therapy, and the drug . They will also receive either saruparib or a placebo.The study is “quadruple-blind,” meaning that neither the patients nor the doctors, examiners, nor data analysts know who is receiving the actual drug. This is intended to ensure that the results are objective. The of the study is -free survival for up to 93 months—that is, the length of time the patient lives without developing metastases.

Men aged 18 and older with confirmed prostate cancer that is classified as high-risk or very high-risk, or in whom the has risen again after surgery (biochemical recurrence), are eligible to participate. A confirmed BRCA1 or BRCA2 mutation in the tumor tissue is a prerequisite. In addition, patients must have completed a planned course of radiation therapy and must not have distant metastases.

Facts

  1. What disease: (prostate carcinoma)
  2. Cancer characteristics: localized or locally advanced, high-risk type, BRCA1 or BRCA2 , no distant metastases (M0), post-radiation status
  3. What the study investigates: Efficacy of the study drug saruparib () in addition to (radiation therapy + anti-hormone therapy +/- )
  4. Study objective: To prolong the time to (metastasis-free survival)
  5. How long will the study last: Treatment and for up to 11 years (total duration until approximately 2036)
  6. Study characteristics: Phase 3 study

Trial sites

28 trial sites in Germany are listed. Find a site near you.

  • Universitätsklinikum Augsburg

    Stenglinstrasse 2, 86156 Augsburg

    Recruiting
  • Charité – Universitätsmedizin Berlin

    Chariteplatz 1, 10117 Berlin

    Recruiting
  • Städtisches Klinikum Braunschweig gGmbH

    Fichtengrund 1, 38126 Braunschweig

    Recruiting
  • Universitätsklinikum Carl Gustav Carus Dresden

    Fetscherstrasse 74, 01307 Dresden

    Status unknown
  • Urologicum Duisburg

    Fahrner Str 123, 47169 Duisburg

    Status unknown
  • Universitätsklinikum Düsseldorf

    Düsseldorf

    Recruiting

This list is compiled to the best of our knowledge but without guarantee: it may be incomplete, and a site's recruitment status can change at any time. Last checked against the trial registers on .

Medical editorial team

  • Dr. med. Sebastian SommerSpecialist in internal medicine with a focus on hematology and oncology
  • PD Dr. med. Matthias FröhlichSpecialist in internal medicine, immunology and emergency medicine

This description is based on the public trial registry entry and was translated into plain language by our medical editorial team. Whether participation is an option for you is a decision you make together with your treating physician.